Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence.

Gilhus, N E

Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence. [electronic resource] - European journal of neurology 12 2018 - 1402-1409 p. digital

Publication Type: Journal Article; Review

1468-1331

10.1111/ene.13788 doi


Adult
Autoantibodies
Family
Female
Humans
Immunoglobulins, Intravenous--adverse effects
Immunosuppressive Agents--adverse effects
Infant, Newborn
Myasthenia Gravis--drug therapy
Neuromuscular Diseases
Pregnancy
Prenatal Exposure Delayed Effects--immunology
Pyridostigmine Bromide--adverse effects
Receptor Protein-Tyrosine Kinases--immunology
Receptors, Cholinergic--immunology